alendronate has been researched along with cholecalciferol in 51 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 24 (47.06) | 29.6817 |
| 2010's | 23 (45.10) | 24.3611 |
| 2020's | 4 (7.84) | 2.80 |
| Authors | Studies |
|---|---|
| Lesser, GT | 1 |
| Hahn, EG; Harsch, IA; Hensen, J; Hübner, RH | 1 |
| Hayashi, Y | 1 |
| Shiraki, M | 2 |
| Kobayashi, S; Shiraki, M; Takaoka, K | 1 |
| Okada, N | 1 |
| Gurevich, B; Ish-Shalom, S; Raz, B; Segal, E; Siebzehner, MI; Tamir, A; Zinnman, C | 1 |
| Curran, MP; Reynolds, NA | 1 |
| Kuroda, T; Miyakawa, N; Orimo, H | 1 |
| Epstein, S | 1 |
| Benhamou, L; Delmas, PD; Emkey, R; Felsenberg, D; Hawkins, F; He, W; Lippuner, K; Lips, P; Recker, R; Rosen, C; Salzmann, G; Santora, AC | 1 |
| Sato, S | 1 |
| Hagino, H | 1 |
| Bergman, G; Gaugris, S; Jansen, JP; Sen, SS | 1 |
| Fassino, V; Mascia, ML; Minisola, S; Pepe, J; Petrucci, MT; Piemonte, S; Romagnoli, E | 1 |
| Antoniucci, DM; Black, DM; Palermo, L; Sellmeyer, DE; Vittinghoff, E | 1 |
| Binkley, N; Holick, MF; Lamotta, A; Liu, M; Ljunggren, O; Minne, HW; Reed, JI; Ringe, JD; Santora, AC; West, JA | 1 |
| Bender, T; Gaál, J; Horváth, I; Kiss, J; Somogyi, P; Surányi, P; Varga, J | 1 |
| Soen, S | 1 |
| Kuroda, T; Miyakawa, N; Miyazaki, T; Shiraki, M | 1 |
| Berry, SD; Hannan, MT; Kiel, DP; Misra, D | 1 |
| Chavez-Eng, C; Constanzer, M; Denker, AE; Gottesdiener, K; Larson, P; Lazarus, N; Maganti, L; Porras, A; Ramakrishnan, R; Scott, BB; Wagner, JA; Woolf, E | 1 |
| Berd, Y; Field, MP; Hansen, KE; Kendler, DL; Mantz, AM; Robson, R; Santora, AC; Shapses, SA; Sherrell, RM; Woolf, E | 1 |
| Binkley, N; Boonen, S; Chen, L; Kiel, DP; Ralston, SH; Reginster, JY; Rosenberg, E; Roux, C; Santora, A | 1 |
| Chouha, F; Djandji, M; Hanley, DA; Karaplis, AC; Sampalis, JS | 1 |
| Jayaraman, M; Karikumar, K; Modi, KD; Verma, A | 1 |
| Hudakova, O; Kozlowski, KS; Marik, IA; Marikova, A; Samuels, ME | 1 |
| Lim, SK; Park, BW; Park, HS; Park, S; Rhee, Y; Song, K | 1 |
| Bonnick, S; Chapurlat, R; DaSilva, C; De Villiers, T; Gurner, D; Le Bailly De Tilleghem, C; Leung, AT; Odio, A; Palacios, S; Scott, BB | 1 |
| Baek, HS; Byun, DW; Choi, SH; Chung, DJ; Chung, YS; Han, KO; Kim, IJ; Kim, KJ; Kim, KM; Kim, M; Kim, SS; Kim, YS; Koh, JM; Lim, SK; Min, KW; Min, YK; Mok, JO; Moon, SH; Park, HM; Park, JS; Shin, CS | 1 |
| Abetel, G; Ferrari, S | 1 |
| Campagna, G; Cesareo, R; Cianni, R; Di Stasio, E; Grimaldi, F; Manfrini, S; Palermo, A; Pasqualini, V; Romitelli, F; Vescini, F | 1 |
| Ahmed Khan, O; Derzko, C; Dubois, S; Khan, A; Khan, AA; Syed, HT; Zohair Rahman, M | 1 |
| Fukuda, F; Ikeda, S; Inoue, T; Ito, M; Mizunuma, H; Nakamura, T; Saito, H; Sakai, A; Tomomitsu, T; Tsurukami, H | 1 |
| Chen, DC; Cheng, Q; De Peng, Y; Hao, YQ; He, L; Hu, ZH; Liao, EY; Lin, H; Santora, AC; Song, CL; Tang, H; Wang, J; Wang, L; Wei, F; Xia, WB; You, L; Zhang, L; Zhang, ZL | 1 |
| Black, DM; Brandi, ML; Cianferotti, L; Fossi, C; Gronchi, G; Parri, S; Rizzuti, C | 1 |
| Brown, TT; Kendall, MA; McComsey, GA; Natsag, J; Sellmeyer, DE | 1 |
| Cadarette, SM; Jandoc, R; Lévesque, LE; Mamdani, M | 1 |
| Atsumi, Y; Cho, H; Masuda, M; Morinaga, S; Oshima, T; Rino, Y; Sato, T; Shiozawa, M; Yamamoto, N; Yoshikawa, T; Yukawa, N | 1 |
| Chen, DC; Cheng, Q; Hao, YQ; He, L; Hu, ZH; Liao, EY; Lin, H; Peng, YD; Song, CL; Tang, H; Wang, J; Wang, L; Wei, F; Xia, WB; You, L; Zhang, L; Zhang, ZL | 2 |
| Luevitoonvechkij, S; Ongphiphadhanakul, B; Robert, CS; Robert, L; Rojanasthien, S; Santora, AC; Songpatanasilp, T; Sugkraroek, P | 1 |
| Di Bonito, M; Ferretti, V; Giampà, E; Nuvoli, G; Paoletti, F; Piazzini, M; Ranieri, M; Tuveri, MA; Vinicola, V | 1 |
| Shang, W; Song, K; Yang, X; Zhou, K | 1 |
| Akin, EB; Barlas, IS; Ecder, ST; Koç, Y; Sinangil, A; Uçar, ZA | 1 |
| Mard, SA; Moradinejad, M; Rakhshan, V; Razavi, SM; Shahsanaei, F; Shamohammadi, M; Yazdi, M | 1 |
| Cai, DZ; Feng, B; Li, Y; Peng, HM; Qian, W; Wan, S; Weng, XS; Yang, Y; Yao, ZJ; Zhang, C; Zhao, C | 1 |
10 review(s) available for alendronate and cholecalciferol
| Article | Year |
|---|---|
[Advancement of treatment for osteoporosis].
Topics: Alendronate; Bone Density; Cholecalciferol; Clinical Trials as Topic; Estrogen Replacement Therapy; Etidronic Acid; Fractures, Bone; Humans; Hydroxycholecalciferols; Osteoporosis; Raloxifene Hydrochloride; Vitamin K 2 | 2002 |
[Treatment of osteoporosis--a new paradigm].
Topics: Alendronate; Bone Density; Cholecalciferol; Diphosphonates; Drug Design; Fractures, Bone; Humans; Osteoporosis; Parathyroid Hormone; Reference Standards; Risk; Selective Estrogen Receptor Modulators; Strontium | 2004 |
[Treatment of osteoporosis combined with a bisphosphonate and vitamin D3].
Topics: Alendronate; Bone Density; Cholecalciferol; Drug Therapy, Combination; Etidronic Acid; Humans; Multicenter Studies as Topic; Osteoporosis; Prognosis; Randomized Controlled Trials as Topic; Spinal Fractures | 2004 |
[Measures for osteoporosis in the dermatological field--vitamin D3 and bisphosphonate].
Topics: Aged; Alendronate; Anti-Inflammatory Agents; Bone Density; Cholecalciferol; Drug Therapy, Combination; Evidence-Based Medicine; Female; Humans; Lumbar Vertebrae; Male; Meta-Analysis as Topic; Middle Aged; Osteoporosis; Prednisolone; Skin Diseases | 2004 |
Alendronate/colecalciferol.
Topics: Alendronate; Biological Availability; Cholecalciferol; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Maximum Tolerated Dose; Osteoporosis; Randomized Controlled Trials as Topic | 2005 |
[Current research in adequate treatment by Osteoporosis Research Group].
Topics: Alendronate; Bone Density Conservation Agents; Cholecalciferol; Clinical Trials as Topic; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Japan; Osteoporosis; Practice Guidelines as Topic; Research; Societies, Medical; Spinal Fractures | 2006 |
[Secondary osteoporosis. Evidence of treatment efficacy in patients with glucocorticoid-induced osteoporosis].
Topics: Alendronate; Bone Density Conservation Agents; Calcitonin; Cholecalciferol; Etidronic Acid; Evidence-Based Medicine; Glucocorticoids; Humans; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Vitamin K 2 | 2007 |
[Combination therapy for osteoporosis].
Topics: Alendronate; Bone Density Conservation Agents; Calcitonin; Calcium; Cholecalciferol; Diphosphonates; Drug Therapy, Combination; Humans; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Vitamin K 2 | 2007 |
[Drug therapy of secondary osteoporosis: glucocorticoid-induced osteoporosis].
Topics: Alendronate; Bone Density Conservation Agents; Cholecalciferol; Clinical Trials as Topic; Diphosphonates; Glucocorticoids; Humans; Osteoporosis; Practice Guidelines as Topic; Spinal Fractures; Vitamin K 2 | 2009 |
[A-TOP research group/JOINT program].
Topics: Alendronate; Bone Density Conservation Agents; Cholecalciferol; Drug Therapy, Combination; Evidence-Based Medicine; Fractures, Bone; Fractures, Spontaneous; Humans; Japan; Multicenter Studies as Topic; Osteoporosis; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Societies, Medical; Vitamin K 2 | 2009 |
19 trial(s) available for alendronate and cholecalciferol
| Article | Year |
|---|---|
Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial.
Topics: Aged; Alendronate; Bone and Bones; Cholecalciferol; Double-Blind Method; Drug Combinations; Female; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Parathyroid Hormone; Postmenopause; Vitamin D | 2006 |
Vitamin D insufficiency does not affect response of bone mineral density to alendronate.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Cholecalciferol; Female; Femur Neck; Hip Joint; Humans; Osteoporosis, Postmenopausal; Spine; Vitamin D; Vitamin D Deficiency | 2009 |
Alendronate/vitamin D3 70 mg/2800 IU with and without additional 2800 IU vitamin D3 for osteoporosis: results from the 24-week extension of a 15-week randomized, controlled trial.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Cholecalciferol; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypercalciuria; Male; Osteoporosis; Postmenopause | 2009 |
Low acceptance of treatment in the elderly for the secondary prevention of osteoporotic fracture in the acute rehabilitation setting.
Topics: Acute Disease; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Calcium; Cholecalciferol; Female; Fractures, Bone; Humans; Male; Medication Adherence; Osteoporosis; Patient Acceptance of Health Care; Refusal to Participate; Rehabilitation Centers; Vitamin D; Vitamins | 2010 |
Bioavailability of alendronate and vitamin D(3) in an alendronate/vitamin D(3) combination tablet.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alendronate; Area Under Curve; Biological Availability; Bone Density Conservation Agents; Cholecalciferol; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Male; Middle Aged; Tablets; Young Adult | 2011 |
Effect of alendronate and vitamin D₃ on fractional calcium absorption in a double-blind, randomized, placebo-controlled trial in postmenopausal osteoporotic women.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Calcium; Cholecalciferol; Double-Blind Method; Endpoint Determination; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Placebos | 2011 |
Randomized trial of alendronate plus vitamin D3 versus standard care in osteoporotic postmenopausal women with vitamin D insufficiency.
Topics: Accidental Falls; Aged; Aged, 80 and over; Alendronate; Algorithms; Bone Density; Bone Density Conservation Agents; Cholecalciferol; Diphosphonates; Drug Combinations; Female; Humans; Osteoporosis, Postmenopausal; Postmenopause; Standard of Care; Vitamin D Deficiency | 2011 |
Efficacy of a combined alendronate and calcitriol agent (Maxmarvil®) in Korean postmenopausal women with early breast cancer receiving aromatase inhibitor: a double-blind, randomized, placebo-controlled study.
Topics: Alendronate; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Resorption; Breast Neoplasms; Calcitriol; Calcium, Dietary; Cholecalciferol; Collagen Type I; Combined Modality Therapy; Dietary Supplements; Double-Blind Method; Drug Combinations; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Patient Dropouts; Peptides; Postmenopause; Republic of Korea | 2013 |
Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial.
Topics: Aged; Alendronate; Biomarkers; Biphenyl Compounds; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Calcium, Dietary; Cathepsin K; Cholecalciferol; Combined Modality Therapy; Dietary Supplements; Double-Blind Method; Drug Monitoring; Female; Humans; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Patient Dropouts; Protease Inhibitors | 2013 |
Efficacy and safety of weekly alendronate plus vitamin D₃ 5600 IU versus weekly alendronate alone in Korean osteoporotic women: 16-week randomized trial.
Topics: Adult; Aged; Alendronate; Cholecalciferol; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Vitamin D Deficiency | 2014 |
Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism.
Topics: Administration, Oral; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Cholecalciferol; Drug Combinations; Female; Femur; Humans; Hyperparathyroidism, Primary; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Prospective Studies | 2015 |
A randomized, double-blind, placebo-controlled study to evaluate the effects of alendronate on bone mineral density and bone remodelling in perimenopausal women with low bone mineral density.
Topics: Adult; Alendronate; Bone Density Conservation Agents; Bone Remodeling; Cholecalciferol; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Middle Aged; Osteoporosis; Perimenopause | 2014 |
Efficacy of combined treatment with alendronate (ALN) and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Calcium; Cholecalciferol; Drug Therapy, Combination; Female; Humans; Japan; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Radiography; Treatment Outcome; Vitamin D | 2015 |
Alendronate sodium/vitamin D3 combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: a 6-month, randomized, open-label, active-comparator-controlled study with a 6-month extension.
Topics: Aged; Alendronate; Biomarkers; Bone Density Conservation Agents; Bone Remodeling; Calcitriol; Cholecalciferol; Drug Combinations; Female; Femur Neck; Hip Joint; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Tablets; Vitamin D | 2015 |
Vitamin D, osteoprotegerin/receptor activator of nuclear factor-kappaB ligand (OPG/RANKL) and inflammation with alendronate treatment in HIV-infected patients with reduced bone mineral density.
Topics: Adult; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Resorption; Cholecalciferol; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; Humans; Lumbar Vertebrae; Male; Middle Aged; RANK Ligand; Treatment Outcome | 2016 |
Calcifediol (25-hydroxyvitamin D) improvement and calcium-phosphate metabolism of alendronate sodium/vitamin D
Topics: Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Calcifediol; Calcium Phosphates; China; Cholecalciferol; Female; Humans; Hypercalciuria; Middle Aged; Osteoporosis, Postmenopausal; Treatment Outcome; Vitamin D; Vitamin D Deficiency | 2018 |
Clinical characteristics associated with bone mineral density improvement after 1-year alendronate/vitamin d3 or calcitriol treatment: Exploratory results from a phase 3, randomized, controlled trial on postmenopausal osteoporotic women in China.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Calcitriol; China; Cholecalciferol; Dietary Supplements; Female; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Time Factors; Treatment Outcome | 2018 |
Open-label study of treatment with alendronate sodium plus vitamin D in men and women with osteoporosis in Thailand.
Topics: Administration, Oral; Aged; Alendronate; Bone Density Conservation Agents; Cholecalciferol; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Osteoporosis; Thailand; Treatment Outcome; Vitamin D | 2018 |
Effect of alendronate sodium plus vitamin D
Topics: Alendronate; Cholecalciferol; Double-Blind Method; Humans; Knee Joint; Multicenter Studies as Topic; Osteoarthritis, Knee; Pain; Quality of Life; Randomized Controlled Trials as Topic; Tablets; Treatment Outcome; Vitamin D | 2022 |
22 other study(ies) available for alendronate and cholecalciferol
| Article | Year |
|---|---|
Long-term prevention of bone loss.
Topics: Alendronate; Bone Density; Calcium, Dietary; Cholecalciferol; Dietary Supplements; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal | 2000 |
[Osteoporosis and multiple pregnancy--a case report with positive outcome].
Topics: Adult; Alendronate; Bone Density; Calcium Channel Agonists; Calcium, Dietary; Cholecalciferol; Contraindications; Drug Therapy, Combination; Female; Fractures, Spontaneous; Humans; Osteoporosis; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Pregnancy, Multiple; Pubic Bone; Radiography; Secondary Prevention; Treatment Outcome | 2001 |
[Evidence-based assessment of therapeutic agents of osteoporosis. Bisphosphonates, SERM and basic therapy in front].
Topics: Age Factors; Aged; Alendronate; Calcium; Cholecalciferol; Diphosphonates; Drug Therapy, Combination; Evidence-Based Medicine; Female; Humans; Male; Meta-Analysis as Topic; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Practice Guidelines as Topic; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Sex Factors | 2003 |
Second hip fracture in elderly hip fracture patients: cost and effectiveness of fracture prevention treatment.
Topics: Aged; Alendronate; Calcium; Cholecalciferol; Costs and Cost Analysis; Hip Fractures; Humans; Osteoporosis; Recurrence | 2005 |
[Progress for patients with osteoporosis].
Topics: Alendronate; Awards and Prizes; Bone Density Conservation Agents; Cholecalciferol; Clinical Trials as Topic; Drug Combinations; Female; Germany; Humans; Male; Osteoporosis; Practice Guidelines as Topic | 2006 |
[Very old patients with osteoporosis should be treated with alendronate].
Topics: Age Factors; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Resorption; Cholecalciferol; Cohort Studies; Female; Follow-Up Studies; Humans; Osteoporosis, Postmenopausal; Retrospective Studies; Spinal Fractures; Vitamin K 2 | 2006 |
The problem of low levels of vitamin D and osteoporosis: use of combination therapy with alendronic acid and colecalciferol (vitamin D3).
Topics: Alendronate; Bone and Bones; Bone Density Conservation Agents; Calcium; Cholecalciferol; Drug Combinations; Humans; Osteoporosis; Vitamin D; Vitamin D Deficiency | 2006 |
Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cholecalciferol; Cost-Benefit Analysis; Diphosphonates; Drug Combinations; Drug Costs; Female; Fractures, Bone; Humans; Ibandronic Acid; Middle Aged; Models, Economic; Netherlands; Osteoporosis; Patient Compliance; Patient Simulation; Quality-Adjusted Life Years; United Kingdom | 2008 |
The effects of alendronate treatment in osteoporotic patients affected by monoclonal gammopathy of undetermined significance.
Topics: Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Density Conservation Agents; Calcium, Dietary; Cholecalciferol; Collagen Type I; Drug Therapy, Combination; Female; Femur; Humans; Lumbar Vertebrae; Male; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Osteocalcin; Osteopontin; Osteoporosis, Postmenopausal; Peptides; Radiography; Spinal Fractures | 2008 |
Overcoming resistance to bisphosphonates through the administration of alfacalcidol: results of a 1-year, open follow-up study.
Topics: Absorptiometry, Photon; Aged; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Cholecalciferol; Diphosphonates; Drug Resistance; Drug Therapy, Combination; Female; Follow-Up Studies; Fractures, Bone; Humans; Hungary; Hydroxycholecalciferols; Male; Middle Aged; Osteoporosis; Time Factors; Treatment Outcome | 2009 |
[Patient compliance program aids therapy success].
Topics: Alendronate; Bone Density Conservation Agents; Calcium; Cholecalciferol; Clinical Trials as Topic; Drug Therapy, Combination; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; Risedronic Acid; Time Factors | 2009 |
Vitamin D status and response to daily 400 IU vitamin D3 and weekly alendronate 70 mg in men and women with osteoporosis.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Canada; Cholecalciferol; Cohort Studies; Dietary Supplements; Female; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; Prospective Studies; Treatment Outcome; Vitamin D | 2011 |
Alendronate therapy in polyostotic fibrous dysplasia presenting with pathologic fracture.
Topics: Adolescent; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium Carbonate; Cholecalciferol; Diagnosis, Differential; Drug Therapy, Combination; Female; Fibrous Dysplasia, Polyostotic; Fractures, Bone; Humans; Radiography; Treatment Outcome | 2011 |
Bisphosphonate therapy for painless fracture: change of HSAN 1 clinical course with biphosphonate and Vitamin D therapy.
Topics: Alendronate; Cholecalciferol; Diphosphonates; Female; Fractures, Bone; Hereditary Sensory and Autonomic Neuropathies; Humans; Vitamin D | 2012 |
[Osteoporotic fractures: not only in females].
Topics: Aged; Alendronate; Bone Density Conservation Agents; Calcitonin; Calcium; Cholecalciferol; Humans; Lumbosacral Region; Male; Osteoporosis; Osteoporotic Fractures | 2014 |
Changing patterns of prescription in vitamin D supplementation in adults: analysis of a regional dataset.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cholecalciferol; Databases, Factual; Dietary Supplements; Drug Costs; Drug Prescriptions; Humans; Italy; Middle Aged; Practice Patterns, Physicians'; Retrospective Studies; Vitamin D; Vitamin D Deficiency; Young Adult | 2015 |
Urban-rural differences in the uptake of new oral bisphosphonate formulations.
Topics: Administration, Oral; Aged; Alendronate; Bone Density Conservation Agents; Cholecalciferol; Diphosphonates; Female; Humans; Male; Ontario; Osteoporosis; Patient Acceptance of Health Care; Risedronic Acid; Rural Health; Urban Health | 2016 |
Effectiveness of alendronate for bone disorder after gastrectomy for gastric cancer.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Bone Diseases, Metabolic; Cholecalciferol; Cohort Studies; Female; Gastrectomy; Humans; Japan; Male; Middle Aged; Prognosis; Retrospective Studies; Risk Assessment; Statistics, Nonparametric; Stomach Neoplasms; Treatment Outcome | 2017 |
Effects of alendronate and calcifediol compared to alendronate and cholecalciferol in osteoporotic patients.
Topics: Aged; Alendronate; Alkaline Phosphatase; Bone Density; Bone Density Conservation Agents; Calcifediol; Calcium; Cholecalciferol; Drug Therapy, Combination; Exercise; Female; Femur; Humans; Lumbar Vertebrae; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Parathyroid Hormone; Phosphorus; Retrospective Studies; Vitamin D | 2019 |
Oral administration of alendronate and vitamin D3 for the treatment of chronic non-bacterial osteomyelitis of the jaw.
Topics: Administration, Oral; Alendronate; Child, Preschool; Cholecalciferol; Female; Humans; Mandible; Osteomyelitis | 2020 |
The Effect of Alendronate on Bone Mineral Disorder in Renal Transplant Patients.
Topics: Alendronate; Bone Density; Bone Diseases, Metabolic; Calcium; Cholecalciferol; Humans; Kidney Transplantation; Minerals | 2022 |
Efficacy of the systemic co-administration of vitamin D3 in reversing the inhibitory effects of sodium alendronate on orthodontic tooth movement: A preliminary experimental animal study.
Topics: Alendronate; Animals; Biomarkers; Cholecalciferol; Male; Osteoclasts; Rats; Rats, Wistar; Sodium; Tooth Movement Techniques | 2022 |